GSK prepares its kit in GIST
The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials.
The gist of GSK's move is to follow Ono
The UK company buys IRDx for $1bn.
Safety remains in focus for Cogent’s bezuclastinib
An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.
ASH 2023 – the search for a better Ayvakit
Blueprint looks to a next-gen Ayvakit, while Cogent challenges with a molecule acquired from Daiichi Sankyo.
